CD1d-restricted invariant (i)NKT cells are innate-like, lipid-reactive T lymphocytes implicated in the control of infections, cancer and autoimmunity. Our study suggests that the reconstitution of the peripheral iNKT cell compartment, following HLA-haploidentical hematopoietic stem cell transplantation, associates with leukemia control in children a ected by di erent hematological malignancies.
Invariant natural killer T (iNKT) cells are innate-like T lymphocytes bearing conserved invariant V 14-J 18 V 24-J 18 TCR chains in mice and humans, respectively, paired with V 8, V 7 and V 2 in mice and V 11 in humans. 1 iNKT cells recognize microbial and cell-endogenous lipids presented by the MHC class I-like molecule CD1d. 1 iNKT cells acquire constitutive effector functions following lineage-dependent developmental cues, which enables them to rapidly respond to a variety of stimuli without prior Agsensitization. Upon activation, iNKT cells produce copious amounts of different cytokines and they have been implicated in the early control of cell stress and tissue damage related to infections, cancer and autoimmunity. 1 The HLA-haploidentical hematopoietic stem cell transplantation (hHSCT) is a critical therapy for the great majority (75%) of leukemia patients lacking an HLA-identical sibling. 2 The transfer of HSC from relatives that only share half HLA locus with the recipients permits to find an immediate donor for any patient.
2 Purified donorderived HSC are depleted of mature T cells to reduce the risk of GVHD, triggered by the donor/recipient histocompatibility barrier, and infused into patients who are profoundly myeloablated to eliminate both endogenous hemopoiesis and malignant cells. 2 As a result, the immune system that reconstitutes in the recipients derives from the donor HSCs, which generate lymphoid precursors that seed in the thymus and give raise to the T and iNKT lymphocytes that are exported in the periphery. 3 This process is particularly efficient in pediatric patients who maintain a functional thymus. 3 A rapid immunoreconstitution is critical to control the major life threatening events that may occur following hHSCT, such as opportunistic infections and the leukemia recurrences. 3 In light of these characteristics, we thought that hHSCT in pediatric patients with leukemia was a suitable model to investigate human iNKT cell reconstitution, to address the unsolved issues of their maturation dynamics and their role in leukemia relapse control. Due to the difficulty to follow longitudinally the iNKT cell development in healthy donors, only snapshots on the human iNKT cell development at initial (thymus and umbilical cord blood) or late (adult blood) stages were available from cross-sectional studies, showing that: (1) Thymic and neonatal iNKT cells display an immature CD4 + phenotype lacking CD161, the NK terminal differentiation marker, and poor effector cytokine production; 4 Pre-clinical studies also elucidated the iNKT cell role in determining the positive balance between GVL and GVHD in mouse models of HSCT for leukemia. 8 Hence, the potential control of leukemia relapses by human iNKT in the clinically relevant context of hHSCT was an important question.
In our study, 9 we undertook a thorough longitudinal analysis of iNKT cell reconstitution in 22 consecutive pediatric patients undergoing hHSCT after a myeloablative regimen for the treatment of acute leukemia and myelodysplastic syndromes (Fig. 1A) . CD4 + and CD4 -iNKT cell frequency, number, phenotype and effector functions were assessed, in direct comparison with mainstream T cells, in the peripheral blood of recipients at monthly intervals up to 18 mo posthHSCT, correlating their emergence with disease relapse and analyzing their reconstitution and maturation kinetics using mathematical models. The data on the reconstitution dynamics of iNKT cells was further reinforced by adding a crosssectional analysis in a second group of 11 patients, who were in clinical remission for 2-6 y post-hHSCT.
Two major findings were obtained (Fig. 1B) . First, we identified a clearly different population dynamics of the CD4 + and CD4 -iNKT cell subsets. The CD4 + emerged first and increased in the periphery at a rate twice faster than that of the CD4 -cells. Both subsets appeared with an immature CD161 -phenotype; however, the CD4 -cells matured markedly more rapidly than the CD4 + iNKT cells, reaching adult-like frequency of CD61 and IFNc expression already by 6 mo after their first detection. The CD4 + iNKT cells remained the most abundant subset up to 5-6 y post-hHSCT, when the CD4 -cells underwent a brisk expansion resulting in the
CD4
-→ CD4 + iNKT cell ratio typical of adults. These data suggested that the making of a mature iNKT cell repertoire is a slow process regulated by subsetspecific mechanisms. Second, we observed a correlation between the presence of iNKT cells and leukemia remission. iNKT cells fully reconstituted in all 14 patients maintaining remission, whereas they completely failed to reconstitute in the 8 relapsing patients. Although the number of patients analyzed was relatively small, none of the best-known variables (female-to-male combination, donor NK the early post-transplantation period, iNKT cells are an essential part of the effector mosaic that maintains the control on the minimal residual leukemia cells that might have escaped the preparative regimen. This is consistent with other human critical cancer contexts, such as head and neck squamous cell carcinoma, where the disease progression following radiotherapy was found to correlate with a very low iNKT/T cell ratio (, 47 iNKT cells/10 6 T cells) present in the patients. 10 Our findings have also potential clinical implications. The molecular determination of the iNKT cell reconstitution trend following hHSCT could become a predictive therapeutic marker. Furthermore, children who do not properly reconstitute the iNKT cell compartment within the first 2-6 mo after hHSCT could receive infusions of donor-derived iNKT cells to prevent possible leukemia recurrence, with minimal risk of inducing GVHD.
